Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia

This study has been completed.
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00260819
First received: December 1, 2005
Last updated: October 16, 2008
Last verified: March 2007
  Purpose

Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of the factors implicated in high-altitude pulmonary oedema. Plasma ET1 increases in subjects exposed to high altitude and is correlated to pulmonary artery pressure.

The aim of the study is to investigate whether blockade of ET1 receptors would reduce the acute rise in systolic pulmonary artery pressure induced by hypoxia.


Condition Intervention Phase
Hypoxia-Induced Pulmonary Artery Hypertension
Drug: Bosentan
Drug: Bosentam TRACLEER
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia

Resource links provided by NLM:


Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • To investigate whether bosentan compared to placebo reduces hypoxia-induced increase in pulmonary artery pressure in healthy subjects and in subjects with past history of high-altitude pulmonary oedema [ Time Frame: during the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To compare [ Time Frame: during the study ] [ Designated as safety issue: Yes ]
  • pulmonary artery pressure response to exercise, [ Time Frame: during the study ] [ Designated as safety issue: Yes ]
  • exercise capacity, [ Time Frame: during the study ] [ Designated as safety issue: Yes ]
  • oxygen desaturation, [ Time Frame: during the study ] [ Designated as safety issue: Yes ]
  • and to assess the global safety [ Time Frame: during the study ] [ Designated as safety issue: Yes ]

Enrollment: 20
Study Start Date: January 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Experimental and Placebo Comparator administered in random order during to successive experimental phase
Drug: Bosentan
Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
Other Name: TRACLEER
Placebo Comparator: 2
Experimental and Placebo Comparator administered in random order during to successive experimental phase
Drug: Bosentam TRACLEER
Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
Other Name: Bosentam TRACLEER

Detailed Description:

Patients will be examined on a variable load supine bicycle ergometer. The exercise table will be tilted laterally by 20 to 30 degrees to the left. PASP will be assessed using Doppler echocardiography at rest and during during supine bicycle exercise in NORMOXIA and hypoxia. Exposure to normobaric hypoxia will be performed by breathing a hypoxic gas mixture at sea level during 90 minutes (12,3 % O2 + 87.7 % N2) reproducing conditions at 4300 m altitude. Exercise will be started at an initial workload of 40 watts and increased by 10 watts every minute to reach a workload level defined by a heart rate (HR) corresponding to 50% of the estimated maximal aerobic power

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 20 non smoker healthy volunteers : 10 resistant to high-altitude pulmonary oedema and 10 susceptible subjects, without history of cardiac or pulmonary disease or asthma, after a complete clinical examination and safety laboratory measurements prior to randomization, and after giving informed written consent.

Exclusion Criteria:

  • antecedent of lung disease notably with asthmatic antecedent or HTAP
  • antecedent of heart disease
  • female genital organ
  • systolic blood pressure < 85 mmHg or > 160 mmHg after 5 minutes of lengthened rest.
  • sentimentality in a medicine, in particular in a bosentan or in one of the excipients of the tablet.
  • hepatic incapacity moderated to severe correspondent in the class B or C of the classification of Child-Pugh (cf Pharmacokinetics) Rate serous hepatic aminotransferases, aspartate aminotransferases( ASAT) and\or alanine aminotransférases ( ALAT), superior to 3 times the superior limit of the normal before the started of the treatment.
  • pointed or chronic systematic diseases.
  • presence of antibody anti-HIV, of anti-HVC antibody, antigens Hbs and\or antibody anti-Hbc. - active addiction to smoking.
  • alcohol abuse and of toxins.
  • Taking of concomitant medicines except those allowed the chapter concomitant treatments.
  • signs, symptoms or values of the biological examinations situated except the clinically acceptable values for healthy subjects with or without antecedent of OPHA.
  • common(current) ingestion of excessive quantities of tea, coffee(cafe), chocolate and\or drinks containing some caffeine (> 5 cups / day, is approximately 500 mg of caffeine a day).
  • consumption of juice of grapefruit and\or herb tea on base of St.
  • John's wort
  • Don of blood in 3 months preceding the study.
  • Persons in period of exclusion on the national file of the persons lending itself to the biomedical search(research) without direct individual profit.
  • refusal or linguistic or psychic incapacity to sign the lit(enlightened) assent.
  • subject which can not submit itself to the constraints of the protocol (for example, not cooperative, incapable to go(surrender) to the visits of follow-up and probably incapable to finish the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260819

Locations
France
Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou
Paris, France, 75908 cedex 15
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Michel AZIZI, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

Publications:
Responsible Party: Isabelle Brindel, Department Clinical Research of Developpement
ClinicalTrials.gov Identifier: NCT00260819     History of Changes
Other Study ID Numbers: P050502, AOR05038
Study First Received: December 1, 2005
Last Updated: October 16, 2008
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Hypoxia-induced pulmonary artery hypertension
High-altitude pulmonary oedema
ETA receptor antagonist

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases
Bosentan
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014